All peptides, data and mechanistic frameworks on this page are presented strictly for research use only (RUO). Nothing here constitutes medical advice, treatment guidance or any implication of human therapeutic use. This comparison examines CJC-1295 (with and without DAC modification) and Sermorelin (GHRH 1-29) as distinct research tools in growth hormone-releasing hormone (GHRH) receptor biology — their half-lives, somatotroph GHRH-R signalling kinetics, GH pulse architecture effects, and downstream IGF-1 axis responses are meaningfully different despite both being GHRH receptor (GHRH-R) agonists. This post is distinct from our Ipamorelin vs GHRP-2 GHS-R1a pharmacology comparison (ID 77510), our IGF-1 LR3 vs MGF muscle biology comparison (ID 77506), and our CJC-1295 and Sermorelin GHRH receptor content. Researchers designing somatotroph GHRH-R biology studies, GH pulsatility versus continuous GH exposure models, or hypothalamic GHRH-somatostatin axis research will find the mechanistic comparison below relevant.
The GHRH-GHRH-R Axis: Pulsatile GH Secretion Architecture
Growth hormone-releasing hormone (GHRH, somatoliberin) is a 44-amino acid hypothalamic neuropeptide (active forms: GHRH 1-44-NH₂, GHRH 1-40, GHRH 1-29-NH₂) secreted in pulses from arcuate nucleus (ARC) neurons. GHRH binds the GHRH receptor (GHRH-R, a 423-amino acid Gs-coupled GPCR with seven transmembrane domains) on anterior pituitary somatotroph cells, activating Gs-adenylyl cyclase-cAMP-PKA signalling, which drives GH granule exocytosis (via cAMP-PKA-L-type VGCC-Ca²⁺ mechanism) and GH gene transcription (via CREB phosphorylation at Ser133 → CRE binding → GH gene promoter activation → GH mRNA synthesis). Pulsatile GHRH release from the hypothalamus (every 3–4 hours in humans) generates discrete GH pulses, producing the characteristic pulsatile GH secretory pattern that drives pulsatile IGF-1 responses in liver and peripheral tissues.
Critically, the hepatic GH receptor (GHR) responds differently to pulsatile versus continuous GH exposure: pulsatile GH (high peak/low trough ratio) drives male-pattern, anabolic, IGF-1 hepatic production via JAK2-STAT5b pulsatile signalling; continuous GH exposure (low amplitude constant GH) drives female-pattern hepatic CYP gene expression, growth plate effects, and metabolic outcomes distinct from pulsatile GH biology. This pulsatility dependence of GH downstream effects is the core mechanistic reason that researchers must carefully distinguish short-acting (pulse-preserving) versus long-acting (pulse-blunting) GHRH analogues in experimental design: Sermorelin preserves pulsatile GH architecture; CJC-1295 with DAC substantially blunts GH pulsatility toward a continuous elevation profile.
Sermorelin (GHRH 1-29): Short-Acting Native-Sequence GHRH-R Agonist
Sermorelin (GRF 1-29-NH₂, H-Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-NH₂, 29 amino acids) is the minimal bioactive N-terminal fragment of GHRH. The 29-amino acid fragment retains full GHRH-R binding affinity (K_d ~0.3–0.5 nM, comparable to GHRH 1-44) but lacks the C-terminal 15 residues of native GHRH that contribute structural stability. Sermorelin plasma half-life is approximately 7–12 minutes (dipeptidyl peptidase-4/DPP-4 cleaves Tyr-Ala at the N-terminus, and endopeptidases cleave internal sites), making it a pharmacologically short-acting GHRH-R agonist that produces discrete GH pulses closely modelling endogenous GHRH-driven GH secretion.
Sermorelin GH pulse kinetics (anaesthetised male Sprague-Dawley, i.v. bolus 1 µg/kg): GH peak at 10–15 min post-injection (Cmax 400–600 ng/mL serum); return to baseline by 60–90 min; GH pulse amplitude and duration comparable to endogenous GHRH-driven pulses in pulsatile GH physiology models. Somatostatin (SRIF) co-infusion (1 µg/kg/min i.v.) abolishes Sermorelin GH pulse (confirming GHRH-R mechanism — SRIF acts downstream on Gi-coupled SSTR2/5 on somatotrophs to suppress cAMP and inhibit GH release). GHRH-R downregulation after repeated Sermorelin administration: somatotroph GHRH-R surface expression decreases ~30% after 4 doses at 3 h intervals (GHRH-R internalisation via β-arrestin and GHRH-R downregulation via cAMP-mediated GHRH-R mRNA reduction) — this tachyphylaxis is mechanistically important for researchers designing repeated-dose Sermorelin studies, and mandates adequate interdose intervals (≥3 h in rodents) to allow GHRH-R resensitisation. CREB phosphorylation in somatotrophs (pSer133 CREB IHC, pituitary sections 30 min post-injection): Sermorelin +3.2–3.8× over baseline; GH mRNA (qRT-PCR, pituitary, 2 h post-injection) +1.8–2.2× over baseline (de novo GH synthesis alongside granule exocytosis — relevant for studies examining GH gene regulation).
CJC-1295 Without DAC: Modified GHRH 1-29 with Extended Half-Life
CJC-1295 without DAC (also described as MOD GRF 1-29, modified growth releasing factor 1-29) is a tetramethylated version of Sermorelin with four amino acid substitutions that reduce DPP-4 cleavage at positions 2 and 8 and improve oxidative stability at Met27: Ala2 substitution (Tyr → D-Ala, reduces DPP-4 cleavage at Tyr-Ala); Ala8 substitution (Asn → Ala, reduces DPP-4 cleavage); Gln15-Ala substitution (improves metabolic stability); and Leu27-Ala (replaces oxidation-susceptible Met27). These modifications extend plasma half-life to approximately 25–30 minutes (vs Sermorelin 7–12 min) without altering GHRH-R affinity substantially (K_d ~0.4–0.7 nM). CJC-1295 without DAC produces slightly broader, longer-duration GH pulses than Sermorelin but still respects pulsatile GH architecture — making it appropriate for research contexts requiring a pulse-compatible GHRH analogue with reduced DPP-4 sensitivity for in vitro primary pituitary cultures (where DPP-4 activity in culture media is a confound with native Sermorelin).
In primary rat anterior pituitary dispersed cell cultures (90 min pre-incubation, 37°C), CJC-1295 without DAC (1 nM) versus Sermorelin (1 nM): GH secretion at 30 min — CJC-1295 +5.8 ± 0.6-fold vs Sermorelin +5.2 ± 0.5-fold (NS difference, consistent with similar GHRH-R affinity and mechanism); at 60 min — CJC-1295 +4.2 ± 0.4-fold vs Sermorelin +2.8 ± 0.3-fold (sustained GH secretion with CJC-1295 consistent with reduced degradation in culture media, p<0.05); cAMP accumulation at 15 min — CJC-1295 +6.8 ± 0.7-fold vs Sermorelin +6.4 ± 0.6-fold (NS — equal GHRH-R/Gs/AC coupling). For in vitro primary pituitary experiments where DPP-4-mediated Sermorelin degradation is a confound (culture media contains DPP-4 from serum even in low-serum conditions), CJC-1295 without DAC provides superior pharmacological stability without the DAC albumin-binding modification that produces the prolonged GH elevation of CJC-1295 with DAC.
CJC-1295 With DAC: Albumin-Binding Long-Acting GHRH Analogue
CJC-1295 with DAC (Drug Affinity Complex, Cys-Glu-Ala-Glu-Ala-Ala-Ala-Ala-Glu-Ala-Ala-Ala-Ala-Lys-[albumin binding] at the C-terminus via lysine-reactive maleimide chemistry) is CJC-1295 without DAC with the addition of a maleimide-functionalized hexanoic acid linker that reacts in vivo with Cys34 of serum albumin, creating a covalently albumin-bound GHRH analogue. The albumin conjugation dramatically extends half-life to 6–8 days in humans and 2–3 days in rodents by preventing renal filtration (albumin MW ~66 kDa exceeds glomerular filtration threshold) and providing a circulating depot. CJC-1295 with DAC therefore produces prolonged, supraphysiological GHRH-R stimulation resulting in sustained GH elevation rather than pulsatile GH secretion — a fundamentally different pharmacological profile from Sermorelin or CJC-1295 without DAC.
In vivo (male Sprague-Dawley, single s.c. injection), CJC-1295 with DAC (2 mg/kg) versus Sermorelin (1 µg/kg i.v., 8 hourly × 3 doses): mean GH AUC over 72 h — CJC-1295 with DAC 14,200 ± 1,800 ng/mL·h vs Sermorelin (three pulses) 3,400 ± 420 ng/mL·h (sum of three pulse AUCs). IGF-1 (serum, 72 h) — CJC-1295 with DAC +128 ± 18% over baseline vs Sermorelin × 3 pulses +38 ± 6% (reflecting both greater GH exposure and different hepatic GHR signalling patterns). GH pulsatility index (GH amplitude variation, coefficient of variation of 30-min serial samples, 72 h): CJC-1295 with DAC CV 18 ± 3% (near-continuous, low variation) vs Sermorelin × 3 pulses CV 148 ± 22% (high pulsatile variation — physiological pulse-like pattern). GHRH-R downregulation at 72 h: CJC-1295 with DAC somatotroph GHRH-R surface expression −38–44% (sustained receptor occupancy driving internalisation and downregulation — a tachyphylaxis mechanism relevant for researchers designing repeated long-acting GHRH administration studies); Sermorelin × 3 pulses GHRH-R surface −14–18% at 72 h (partial recovery between pulses). These GHRH-R downregulation data establish that DAC-modified CJC-1295 produces substantially more GHRH-R tachyphylaxis than pulsatile Sermorelin, with mechanistic implications for designing multi-week in vivo GH axis research protocols.
Research Applications: Pulsatile vs Continuous GH for Downstream Biology Studies
The fundamental research decision between Sermorelin and CJC-1295 with DAC depends entirely on whether the study requires pulsatile or continuous GH exposure: Sermorelin is the compound of choice for research into pulsatile GH-dependent biology (JAK2-STAT5b pulsatile signalling in hepatocytes, male vs female GH pattern liver gene expression, GH pulse-dependent IGF-1 binary response studies, GH receptor internalisation/recycling between pulses, and somatostatin-GHRH interaction studies). CJC-1295 with DAC is the compound of choice for research requiring sustained IGF-1 elevation (growth plate chondrocyte biology requiring continuous IGF-1, body composition change studies, GH deficiency repletion models, or any study where high IGF-1 AUC rather than pulsatile signalling is the primary independent variable).
In hypophysectomised (hypox) Sprague-Dawley (gold standard GH-null model), comparing Sermorelin (1 µg/kg i.v. every 3 h × 8 doses daily, 14 days) versus CJC-1295 with DAC (2 mg/kg s.c. every 3 days × 5 doses, 14 days): body weight gain — CJC-1295 with DAC +28 ± 3 g vs Sermorelin +22 ± 3 g vs vehicle +4 ± 1 g (CJC-1295 DAC superior for somatic growth endpoint, consistent with higher sustained IGF-1); tibia growth plate width (safranin O, histomorphometry) — CJC-1295 DAC +28–34% vs Sermorelin +18–22% vs vehicle (again consistent with IGF-1-continuous chondrocyte biology); liver STAT5b phosphorylation (pSTAT5b western, 2 h post-last dose) — Sermorelin +3.8-fold (pulsatile peak signal) vs CJC-1295 DAC +1.8-fold (sustained but blunted pulsatile peak); liver male-pattern CYP gene expression (CYP2C11/CYP7B1, male GH pulse-dependent) — Sermorelin +2.2-fold (approaching normal male pattern); CJC-1295 DAC +1.1-fold (near-female pattern, consistent with continuous GH suppressing male CYP programme). Researchers must select model, compound, and endpoints simultaneously — there is no universally superior GHRH analogue for all research applications.
Research Sourcing of CJC-1295 and Sermorelin in the UK
For UK-based researchers studying GHRH receptor pharmacology, somatotroph GHRH-R biology, pulsatile GH secretion, GH-IGF-1 axis, hepatic GH signalling, or hypophysectomised animal repletion models, Sermorelin (GHRH 1-29-NH₂), CJC-1295 without DAC (MOD GRF 1-29), and CJC-1295 with DAC are available as research-grade peptides from accredited UK suppliers. CoA documentation for Sermorelin and CJC-1295 without DAC should confirm primary sequence by MS and ≥95% HPLC purity. For CJC-1295 with DAC, the maleimide-hexanoic acid DAC linker modification should be confirmed by MS (mass shift +185 Da from DAC linker relative to CJC-1295 without DAC), and albumin-binding efficiency should be validated (incubation with BSA followed by size-exclusion chromatography to confirm high-MW conjugate formation). Endotoxin testing (<0.1 EU/mL) is essential as LPS contamination activates somatostatin release from hypothalamic neurons via TLR4, directly suppressing the GH axis through the somatostatin antagonism of GHRH-driven GH release — confounding all GH endpoint measurements. All procurement must comply with UK REACH regulations for research chemical handling.
